Emil D. Kakkis - President & CEO, Director at Ultragenyx Pharmaceutical Inc.

Issuer-level insider activity

Role
President & CEO, Director
Issuer ticker
RARE on Nasdaq
Identity Names, identifiers, and filing context for this profile. 1 identity field
Entity type
Individual
Source evidence Original filing metadata and source links for verification. 1 source field
Source filing history
Open source filing history

Past-year transaction volume for Emil D. Kakkis in Ultragenyx Pharmaceutical Inc.

Buys

Open market
Shares
Avg price
Total value

Sells

Open market
Shares
-54,404
Avg price
$22.80
Total value
-$1,240,411

Net

Past year
Shares
-54,404
Share %
-100%
Total value
-$1,240,411

Reported holdings for Emil D. Kakkis in Ultragenyx Pharmaceutical Inc.

Form 4 holding President & CEO, Director

Ultragenyx Pharmaceutical Inc.

Security class
Common Stock
Shares / value
2,158,985
Estimated value
$48,663,521
Report date
01 Mar 2026
Price
$22.54
Ownership
By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009
Form 4 holding President & CEO, Director

Ultragenyx Pharmaceutical Inc.

Security class
Common Stock
Shares / value
1,758,985
Estimated value
$36,850,735
Report date
16 Apr 2026
Price
$20.95
Ownership
By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200909

Transaction history for Emil D. Kakkis in Ultragenyx Pharmaceutical Inc.

Sym Class Transaction % SEC-reported value SEC-reported price Shares Shares after Date Ownership
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .